1. Home
  2. AGEN vs UCL Comparison

AGEN vs UCL Comparison

Compare AGEN & UCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGEN
  • UCL
  • Stock Information
  • Founded
  • AGEN 1994
  • UCL 2014
  • Country
  • AGEN United States
  • UCL Hong Kong
  • Employees
  • AGEN N/A
  • UCL N/A
  • Industry
  • AGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • UCL Telecommunications Equipment
  • Sector
  • AGEN Health Care
  • UCL Consumer Discretionary
  • Exchange
  • AGEN Nasdaq
  • UCL Nasdaq
  • Market Cap
  • AGEN 87.7M
  • UCL 70.6M
  • IPO Year
  • AGEN 2000
  • UCL 2020
  • Fundamental
  • Price
  • AGEN $5.29
  • UCL $2.73
  • Analyst Decision
  • AGEN Strong Buy
  • UCL
  • Analyst Count
  • AGEN 3
  • UCL 0
  • Target Price
  • AGEN $16.33
  • UCL N/A
  • AVG Volume (30 Days)
  • AGEN 1.2M
  • UCL 142.4K
  • Earning Date
  • AGEN 08-11-2025
  • UCL 08-13-2025
  • Dividend Yield
  • AGEN N/A
  • UCL N/A
  • EPS Growth
  • AGEN N/A
  • UCL N/A
  • EPS
  • AGEN N/A
  • UCL 0.09
  • Revenue
  • AGEN $99,524,000.00
  • UCL $92,256,000.00
  • Revenue This Year
  • AGEN $25.31
  • UCL $6.09
  • Revenue Next Year
  • AGEN N/A
  • UCL $7.01
  • P/E Ratio
  • AGEN N/A
  • UCL $28.30
  • Revenue Growth
  • AGEN N/A
  • UCL 7.65
  • 52 Week Low
  • AGEN $1.38
  • UCL $0.80
  • 52 Week High
  • AGEN $7.34
  • UCL $3.30
  • Technical
  • Relative Strength Index (RSI)
  • AGEN 44.92
  • UCL 63.73
  • Support Level
  • AGEN $5.34
  • UCL $2.32
  • Resistance Level
  • AGEN $6.58
  • UCL $2.99
  • Average True Range (ATR)
  • AGEN 0.44
  • UCL 0.28
  • MACD
  • AGEN -0.16
  • UCL 0.01
  • Stochastic Oscillator
  • AGEN 10.69
  • UCL 69.05

About AGEN Agenus Inc.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

About UCL uCloudlink Group Inc.

Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data related products to enable personal and enterprise users to access mobile internet in more than 100 countries and areas. Leveraging its inventive cloud SIM technology and architecture, the company redefine the mobile data connectivity experience, allowing users to gain access to mobile data traffic allowance shared by network operators on its marketplace. It has aggregated mobile data traffic allowances from 391 MNOs in 163 countries and regions in its cloud SIM architecture. The company derives maximum revenue from Japan.

Share on Social Networks: